Comparative Pharmacology
Head-to-head clinical analysis: NEXAVAR versus SPRYCEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEXAVAR versus SPRYCEL.
NEXAVAR vs SPRYCEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Multikinase inhibitor targeting Raf, VEGFR-2, VEGFR-3, PDGFR-β, c-KIT, Flt-3, and RET kinases, inhibiting tumor growth and angiogenesis.
Dasatinib is a dual tyrosine kinase inhibitor targeting BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. It binds to the ATP-binding site of BCR-ABL and inhibits proliferation and induces apoptosis in Philadelphia chromosome-positive (Ph+) leukemic cells.
400 mg (two 200 mg tablets) orally twice daily approximately 12 hours apart on an empty stomach (at least 1 hour before or 2 hours after a meal).
100 mg orally once daily, with or without food.
None Documented
None Documented
Terminal half-life 25-48 hours; supports twice-daily dosing with steady state achieved in 7-14 days.
Terminal elimination half-life is approximately 3–4 hours for dasatinib, with a longer half-life of 8–10 hours for its active metabolite; clinical context: supports twice-daily dosing.
Fecal (77% as unchanged drug and metabolites), renal (19% as metabolites, <1% as unchanged drug).
Primarily fecal (85%) as unchanged drug and metabolites; renal excretion accounts for <10% of the dose.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor